A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins.
Détails
ID Serval
serval:BIB_8A8923071074
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins.
Périodique
Fertility and Sterility
ISSN
0015-0282 (Print)
ISSN-L
0015-0282
Statut éditorial
Publié
Date de publication
2001
Volume
75
Numéro
6
Pages
1131-1135
Langue
anglais
Résumé
OBJECTIVE: To study the benefits of a low-dose stimulation (LDS) protocol with purified urinary follicle-stimulating hormone in patients with polycystic ovaries who have presented previously with a very high ovarian response to a standard hMG stimulation.
DESIGN: Cohort study.
SETTING: Fertility center in a university hospital.
PATIENT(S): Sixty-one patients involved in an IVF/ICSI program from January 1995 to December 1996.
INTERVENTION(S): The patients were first stimulated with a standard protocol using hMG and presented with a very high ovarian response. These patients were then stimulated a second time using a low-dose protocol. Cryopreserved embryos were transferred in later artificial or natural cycles until to December 1999.
MAIN OUTCOME MEASURE(S): Number of gonadotropin ampules; estradiol level on the day of ovulation induction; follicles, oocytes, and cryopreserved zygotes; fertilization, implantation, and pregnancy rates; and number of ovarian hyperstimulation syndromes (OHSS).
RESULT(S): The number of ampules used, the estradiol level reached, and the number of oocytes obtained were significantly lower under the LDS than the standard protocol. High implantation (21.8%) and clinical pregnancy (38.4%) rates were obtained after LDS. The cumulated deliveries per cycle started and per patient were, respectively, 41.6% and 52.5%. Five patients suffered OHSS with the standard protocol, and none with the LDS.
CONCLUSION(S): The LDS protocol offers a safe and efficient treatment for patients who present with echographic polycystic ovaries and are at risk of an excessive ovarian response to standard IVF stimulation protocols.
DESIGN: Cohort study.
SETTING: Fertility center in a university hospital.
PATIENT(S): Sixty-one patients involved in an IVF/ICSI program from January 1995 to December 1996.
INTERVENTION(S): The patients were first stimulated with a standard protocol using hMG and presented with a very high ovarian response. These patients were then stimulated a second time using a low-dose protocol. Cryopreserved embryos were transferred in later artificial or natural cycles until to December 1999.
MAIN OUTCOME MEASURE(S): Number of gonadotropin ampules; estradiol level on the day of ovulation induction; follicles, oocytes, and cryopreserved zygotes; fertilization, implantation, and pregnancy rates; and number of ovarian hyperstimulation syndromes (OHSS).
RESULT(S): The number of ampules used, the estradiol level reached, and the number of oocytes obtained were significantly lower under the LDS than the standard protocol. High implantation (21.8%) and clinical pregnancy (38.4%) rates were obtained after LDS. The cumulated deliveries per cycle started and per patient were, respectively, 41.6% and 52.5%. Five patients suffered OHSS with the standard protocol, and none with the LDS.
CONCLUSION(S): The LDS protocol offers a safe and efficient treatment for patients who present with echographic polycystic ovaries and are at risk of an excessive ovarian response to standard IVF stimulation protocols.
Mots-clé
Adult, Cohort Studies, Delivery, Obstetric, Dose-Response Relationship, Drug, Embryo Implantation, Estradiol/blood, Female, Fertilization in Vitro, Follicle Stimulating Hormone/administration & dosage, Follicle Stimulating Hormone/therapeutic use, Humans, Menotropins/adverse effects, Menotropins/therapeutic use, Oocytes, Ovarian Hyperstimulation Syndrome/chemically induced, Ovary/drug effects, Polycystic Ovary Syndrome/physiopathology, Pregnancy, Pregnancy Rate, Risk Factors, Specimen Handling, Sperm Injections, Intracytoplasmic
Pubmed
Web of science
Création de la notice
25/01/2008 15:39
Dernière modification de la notice
20/08/2019 14:49